Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer

Publikation: Bidrag til tidsskriftReviewpeer review

DOI

  1. The effects of targeted immune-regulatory strategies on tumor-specific T-cell responses in vitro

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. In vitro 4-1BB stimulation promotes expansion of CD8+ tumor-infiltrating lymphocytes from various sarcoma subtypes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. TAM-ing T cells in the tumor microenvironment: implications for TAM receptor targeting

    Publikation: Bidrag til tidsskriftReviewpeer review

  1. Explaining deep neural networks for knowledge discovery in electrocardiogram analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. ABO blood types and sepsis mortality

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Vaccination against PD-L1 with IO103 a Novel Immune Modulatory Vaccine in Basal Cell Carcinoma: A Phase IIa Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Cytotoxic T cells isolated from healthy donors and cancer patients kill TGFβ-expressing cancer cells in a TGFβ-dependent manner

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

There is mounting evidence that the immune system can spontaneously clear malignant lesions before they manifest as overt cancer, albeit this activity has been difficult to demonstrate in humans. The calreticulin (CALR) exon 9 mutations are driver mutations in patients with chronic myeloproliferative neoplasms (MPN), which are chronic blood cancers. The CALR mutations generate a neo-antigen that is recognized by patient T cells, and T cells isolated from a patient with a CALR-mutation can recognize and kill autologous CALR-mutant cells. Surprisingly, healthy individuals display frequent and strong T cell responses to the CALR neo-antigens too. Furthermore, healthy individuals display immune responses to all parts of the mutant CALR epitope, and the CALR neo-epitope specific responses are memory T cell responses. These data suggest that although healthy individuals might acquire a CALR mutation, the mutant cells can be eliminated by the immune system. Additionally, a small fraction of healthy individuals harbor a CALR exon 9 mutation. Four healthy individuals carrying CALR mutations underwent a full medical examination including a bone marrow biopsy after a median follow up of 6.2 years. None of these patients displayed any signs of CALR-mutant MPN. Additionally, all healthy individuals displayed strong CALR neo-epitope specific T cell responses suggesting that these healthy individuals retained their CALR-mutant cells in the editing stage for several years. Thus, we suggest that CALR-mutant MPN could be a disease model of cancer immuno-editing, as we have demonstrated that CALR-mutant MPN displays all three stages described in the theory of cancer immuno-editing.

OriginalsprogEngelsk
TidsskriftCancer immunology, immunotherapy
Vol/bind69
Udgave nummer2
Sider (fra-til)315-324
Antal sider10
ISSN0340-7004
DOI
StatusUdgivet - feb. 2020

ID: 59227175